3 Dividend Stocks to Double Up On Right Now
The time is right for buying more of these great dividend stocks.
The Zacks Analyst Blog Highlights Advanced Micro Devices, Abbott Laboratories and Micron Technology
AMD, Abbott and Micron showcase strong momentum as AI demand, medical innovation and memory recovery drive growth prospects.
The Beauty Health Company Names Pedro Malha President and Chief Executive Officer - Beauty Health ( NASDAQ:SKIN )
Global Healthcare and Medical Device Executive with More Than 20 Years of Experience Assumes Role Effective October 1 Marla Beck Steps Down, With BeautyHealth Prepared for Its Next Phase of Growth
1 Top ETF I Wouldn't Hesitate to Invest $1,000 Into Right Now
This fund makes it easy to invest in the top dividend stocks.
Growing Diagnostics Arm Supports ABT Stock, Macro Issues Ail
ABT gains momentum with strong FreeStyle Libre sales and Diagnostics growth but global macro headwinds weigh on performance.
3 Top Dividend Stocks to Buy and Hold Forever
These blue chip dividend stocks offer both income and growth potential.
WeRide Named to Fortune's 2025 Change the World List for Its Leading Role in Driving Social Impact with Autonomous Mobility
The company was also included in Fortune's 2025 Future 50 List for demonstrating strong long-term growth potential The company was also included in Fortune's 2025 Future 50 List for demonstrating strong long-term growth potential ...
1 Growth Stock Down 40% to Buy Hand Over Fist Right Now
It is dealing with some short-term issues, but its prospects remain bright.
1 Top Dividend Stock to Buy and Hold Forever
The stock has outperformed the broader market since its 2013 IPO, and can still do so over the long run.
Don't Overlook These 2 Dividend Kings in Today's Volatile Market
These businesses may be "boring," but that's a good thing in today's market.
8 Dividend Growth Stocks Every Investor Should Consider
These dividend powerhouses compound wealth through decades of consecutive increases and sustainable payout ratios.
Practice of law: case studies
Featuring the most innovative work and legal service lawyers have developed for their clients ...
Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA - DexCom ( NASDAQ:DXCM )
At least 60 Dexcom G7 users report hospitalization, with multiple deaths alleged. FDA cited Dexcom for unauthorized material changes that impacted accuracy. Up Next: Wall Street trader's 35-0 strategy goes public this week. See it first → Hunterbrook Media released a short report on ...
Neuromodulation Market is expected to generate a revenue of USD 9.32 Billion by 2032, Globally, at 9.27% CAGR: Verified Market Research®
Lewes, Delaware, Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- The Global Neuromodulation Market Size is projected to grow at a CAGR of 9.27% from 2026 to 2032, according to a new report published by Verified Market Research®.
3 No-Brainer Dividend Stocks to Buy in September
The attraction of these dividend stocks isn't limited to their dividends.
1 Green Flag for AbbVie ( ABBV ) Stock Right Now
Dividends are powerful portfolio boosters, and AbbVie is a dividend dynamo.
Texas Rep. Julie Johnson Sold Up to $885K Worth of 3M Stock - Abbott Laboratories ( NYSE:ABT ) , AbbVie ( NYSE:ABBV )
September 11, 2025 records indicate that Representative Julie Johnson filed a sale of 3M MMM, valued between $59,059 and $885,000. According to the September filing, the transaction occurred on August 14, 2025. Currently, 3M shares are trading down 0.29% at $159.0.
Picard Announces Appointment of Two New Members to its Board of Directors
Appointments strengthen Picard's Board with proven expertise in capital markets and global MedTech leadership Appointments strengthen Picard's Board with proven expertise in capital markets and global MedTech leadership ...
The Zacks Analyst Blog Highlights Broadcom, T-Mobile, Abbott Laboratories, CBL & Associates Properties and Crown Crafts
Zacks Analyst Blog spotlights Broadcom, T-Mobile, Abbott, CBL & Associates, and Crown Crafts with updates on growth, risks, and outlooks.
1 Reason Every Investor Should Know About AbbVie ( ABBV )
This company's past ability to extend patent-protected market exclusivity for its drugs bodes well for new investors.
Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?
There is more to like than the dividend with these companies.
ABT Stock Gains From Navitor's Expanded Indication Approval in Europe
Abbott wins CE Mark in Europe for expanded Navitor use, boosting its Structural Heart business and lifting ABT stock.
ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now?
As the structural heart market expands, Abbott and Edwards battle for leadership. Which stock holds stronger growth momentum now?
If You'd Invested $1,000 in DexCom 10 Years Ago, Here's How Much You'd Have Today
The company's innovative devices have helped it generate decent performances.
What's Driving Abbott's Gross Margin Growth Amid Macro Issues
ABT's gross margin hits 56.4% in Q2, fueled by Medical Devices growth, Nutrition strength, FX tailwinds and cost discipline.
I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee - I-MAB ( NASDAQ:IMAB )
Dr. Robert Lenz, Ms. Xin Liu and Dr. Sean Cao appointed to the Board of Directors Research and Development Committee established to accelerate innovation and long-term growth Dr. Ken Takeshita appointed to the Scientific Advisory Board
3 Unstoppable Dividend Stocks to Buy Right Now
Investors will get great dividends and more with these stocks.
2 High-Yield Dividend Stocks to Buy in August and Hold for a Decade or Longer
These high-yield dividend stocks are built to last.
The Zacks Analyst Blog Highlights Amazon.com, Salesforce, Abbott Laboratories and Fossil Group
Amazon, Salesforce, Abbott and Fossil Group show diverging trends as AI spending weighs on margins, healthcare pipelines expand, and retail turnarounds gain traction.
Abbott Gains in Nutrition With Adult Segment Leading Growth
ABT Nutrition unit posts steady gains as adult-focused brands like Ensure and Glucerna drive global demand and market share growth.
If You'd Invested $1,000 in AbbVie Stock 10 Years Ago, Here's How Much You'd Have Today
You'd be sitting pretty right now.
2 Stocks to Buy on the Dip and Hold for 10 Years
There should be plenty of long-term upside for these stocks for investors willing to ride out the storm.
Looking Into Abbott Laboratories's Recent Short Interest - Abbott Laboratories ( NYSE:ABT )
Abbott Laboratories's ABT short percent of float has fallen 3.64% since its last report. The company recently reported that it has 18.33 million shares sold short, which is 1.06% of all regular shares that are available for trading.
Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data
TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.
3 Dividend Stocks to Double Up On Right Now
These stocks offer great dividends and more.
Abbott Taps Growing TMVR Market With Tendyne System
ABT wins FDA nod for its Tendyne TMVR system, offering a minimally invasive option for patients with severe mitral valve disease.
Recent Filing Shows That Rep. Josh Gottheimer Sold Over $6K Worth of Abbott Laboratories Stock - Abbott Laboratories ( NYSE:ABT )
A August filing shows that Representative Josh Gottheimer reported a sale in Abbott Laboratories ABT, valued between $6,006 and $90,000. The transaction date is listed as July 18, 2025, with the report published on August 11, 2025. At present, Abbott Laboratories shares are trading down 1.0% at ...
3 Stocks Retirees Should Absolutely Love
These stocks check off all the boxes for investors no longer receiving a paycheck.
Abbott's EPD Growth Beats Market Trends: Here's How to Play the Stock
Abbott outpaces market trends as EPD sales surge, fueled by double-digit growth, biosimilar approvals and strong product demand.
Gauzy Ltd. Announces Board of Directors Changes Following Annual Meeting
Gauzy Pleased to Announce Alejandro Weinstein, Former Director in Gauzy, Elected to Board. A Long-Time Investor and Shareholder Engaged with the Company Since ...
Gauzy Ltd. Announces Board of Directors Changes Following Annual Meeting - Gauzy ( NASDAQ:GAUZ )
Gauzy Pleased to Announce Alejandro Weinstein, Former Director in Gauzy, Elected to Board; A Long-Time Investor and Shareholder Engaged with the Company Since 2016 Gauzy Adopts Leaner Board to Reduce Corporate Expenses and Maintain Agility TEL AVIV, Israel, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- ...
Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It?
ABT's Diabetes Care sales surge 19.6% in Q2, fueled by strong U.S. demand and new OTC approvals for its CGM systems.
Reckitt Benckiser Group PLC Investors: Please contact the Portnoy Law Firm to recover your losses. August 4, 2025 Deadline to file Lead Plaintiff Motion - Reckitt Benckiser Group ( OTC:RBGLY )
Investors can contact the law firm at no cost to learn more about recovering their losses
If You'd Invested $1,000 in AbbVie ( ABBV ) Stock 10 Years Ago, Here's How Much You'd Have Today
Spoiler: You would have done well -- and even better if you'd reinvested your dividends.
3 Unstoppable Stocks to Buy in August
Here are hot stocks to buy in a hot month.
2 Top Stocks to Buy Now If You Want Decades of Passive Income
These companies have provided strong returns to long-term shareholders, but they aren't done yet.
Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever
Being a great investor doesn't have to be complicated or expensive.
Former U.S. Attorney Rick Mountcastle Joins Guttman Buschner PLLC and Co-Produces Explosive Nursing Home Docuseries Premiering August 1 on Amazon
WASHINGTON, July 29, 2025 /PRNewswire/ -- Guttman Buschner PLLC is pleased to announce that former United States Attorney Rick Mountcastle has joined the firm as Of Counsel, bringing his decades of nationally recognized litigation and enforcement experience to the firm's robust whistleblower and ...
Glucose Health, Inc. ( OTC: GLUC ) Highlights U.S. Department of Health and Human Services Designation of Key Nutrient Validating Company's Patent-Pending Nutrition Formulation via CNBC, Fox Business and Bloomberg Television Media Blitz
BENTONVILLE, Ark., July 29, 2025 ( GLOBE NEWSWIRE ) -- Glucose Health, Inc. ( OTC: GLUC ) , a publicly traded consumer healthcare company focused on diabetic nutrition and soluble fiber-based nutrition formulations, today announced the launch of a targeted media blitz to bring greater awareness ...
Glucose Health, Inc. ( OTC: GLUC ) Highlights U.S. Department of Health and Human Services Designation of Key Nutrient Validating Company's Patent-Pending Nutrition Formulation via CNBC, Fox Business and Bloomberg Television Media Blitz - Glucose Health ( OTC:GLUC )
BENTONVILLE, Ark., July 29, 2025 ( GLOBE NEWSWIRE ) -- Glucose Health, Inc.
